Elekta AB (OTCMKTS:EKTAY) Short Interest Up 345.3% in July

Elekta AB (OTCMKTS:EKTAY) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 16,311 shares, an increase of 345.3% from the July 15th total of 3,663 shares. Based on an average trading volume of 9,444 shares, the short-interest ratio is currently 1.7 days. Approximately 0.0% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce”.

Elekta Price Performance

Shares of Elekta stock remained flat at $5.42 on Thursday. 2,531 shares of the company traded hands, compared to its average volume of 4,540. The stock has a market cap of $2.00 billion, a P/E ratio of -33.84 and a beta of 1.01. Elekta has a 1-year low of $4.35 and a 1-year high of $6.93. The business has a 50-day moving average of $5.15 and a two-hundred day moving average of $5.76. The company has a quick ratio of 0.68, a current ratio of 0.87 and a debt-to-equity ratio of 0.47.

Elekta (OTCMKTS:EKTAY) last announced its earnings results on Thursday, May 28th. The company reported $0.06 earnings per share (EPS) for the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 11.11%. The company had revenue of $521.00 million during the quarter. As a group, analysts expect that Elekta will post 0.43 earnings per share for the current year.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.